Nkarta (NKTX) Free Cash Flow (2019 - 2026)
Nkarta (NKTX) posted quarterly Free Cash Flow of -$28.6 million for Q1 2026, up 5.04% year-over-year from -$27.2 million in Q1 2025, and down 28.84% quarter-over-quarter from -$22.2 million in Q4 2025.
Nkarta (NKTX) Free Cash Flow (2019 - 2026) Analysis & Trends
Nkarta's Free Cash Flow history runs 8 years deep, the most recent figure standing at -$28.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 5.04% year-over-year to -$28.6 million; the TTM figure through Mar 2026 stood at -$88.4 million (up 16.26% YoY), while the FY2025 annual figure was -$89.9 million, up 13.64% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$28.6 million, down from -$22.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$18.7 million in Q3 2025, with the low at -$42.4 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$25.6 million (2023), against an average of -$25.9 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 127.0% in 2022, then increased 28.81% in 2023.
- Nkarta's Free Cash Flow stood at -$42.4 million in 2022, then climbed by 28.81% to -$30.2 million in 2023, then increased by 14.28% to -$25.9 million in 2024, then increased by 14.11% to -$22.2 million in 2025, then declined by 28.84% to -$28.6 million in 2026.
- Business Quant data shows NKTX's Free Cash Flow at -$28.6 million in Q1 2026, -$22.2 million in Q4 2025, and -$18.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -24.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.41 Mn |
| Jun 30, 2026 | -24.41 Mn |
| Mar 31, 2026 | -28.61 Mn |
| Mar 31, 2026 | -28.61 Mn |
| Dec 31, 2025 | -22.21 Mn |
| Dec 31, 2025 | -22.21 Mn |
| Sep 30, 2025 | -18.68 Mn |
| Sep 30, 2025 | -18.68 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Mar 31, 2025 | -30.13 Mn |
| Dec 31, 2024 | -25.85 Mn |
| Dec 31, 2024 | -25.85 Mn |
| Sep 30, 2024 | -25.32 Mn |
| Sep 30, 2024 | -25.32 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Jun 30, 2024 | -24.25 Mn |
| Mar 31, 2024 | -28.68 Mn |
| Mar 31, 2024 | -28.68 Mn |